Meyka AI API is live for developers.Start building.
Advertisement
Novo Nordisk A/S

Novo Nordisk A/S (NVO) Stock Overview

Explore Novo Nordisk A/S’s financial performance, market position, analyst ratings, and future outlook.

NVOā—NYSE
HealthcareBiotechnology
$42.96
$0.79(1.81%)
U.S. Market opens in 55h 43m
Advertisement

Novo Nordisk A/S (NVO)

Meyka AI Score

Z

Key Financials

Market Cap190.8B
P/E Ratio10.16
EPS (TTM)$4.27
ROE0.66%
Fundamental Analysis

AI Price Forecasts

1 Month$33.15
3 Months$56.35
1 Year Target$0.00

NVO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novo Nordisk A/S (NVO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 46.49, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 10.16 and a market capitalization of 190.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.85%
5-Day Change
-5.58%
1-Month Change
-4.30%
3-Month Change
9.91%
6-Month Change
-10.28%
Year-to-Date (YTD) Change
-15.61%
1-Year Change
-40.89%
3-Year Change
-45.60%
5-Year Change
5.76%
All-Time (Max) Change
26737.50%

Contact Information

45 44 44 88 88
Novo Alle 1, Bagsvaerd, NaN, 2880

Company Facts

77,406 Employees
IPO DateApr 30, 1981
CountryDK
Actively Trading

Frequently Asked Questions